Results From Fully Enrolled NEURO-TTRansform Trial Due Mid-2022

Patient enrollment is complete for the Phase 3 NEURO-TTRansform trial testing Ionis Pharmaceuticals’ eplontersen in adults with familial amyloid polyneuropathy (FAP). The trial exceeded its enrollment target of 140 participants, with Ionis now expecting to register more than 160 patients in the study. “The speed of enrollment…

Alnylam Completes Enrollment for Phase 3 HELIOS-A Trial Testing Vutrisiran

Alnylam Pharmaceuticals announced that it has completed patient enrollment for its Phase 3 HELIOS-A trial of vutrisiran, which will test the safety and efficacy of the candidate therapy for treating hereditary transthyretin amyloidosis. HELIOS-A (NCT03759379) enrolled 160 participants from 68 clinical sites…